Initial Cardiovascular Disease Risk Assessment in Non-Clinical Settings: Framingham-Simplified Model Predictive Performance in a Canadian Cohort

Structured abstract includes objectives, setting, participants, outcomes, and performance.Background Provide a brief explanation of the healthcare context and rationale for developing or evaluating the performance of all models Yes Abstract (Background) States rationale for Framingham-SP, accessibility without labs, lack of Canadian validation.Objectives Specify the study objectives, including whether the study describes model development, evaluation, or both Yes Abstract (Background) States evaluation of discrimination and calibration of Framingham-SP in Canada Methods Describe the sources of data Yes Abstract (Methods) PROQ cohort + medicoadministrative linkage.Describe the eligibility criteria and setting where the data were collected Yes Abstract (Methods) CVD-free adults from a working population in Quebec.Specify the outcome to be predicted by the model, including time horizon of predictions in case of prognostic models Yes Abstract (Methods) First CVD event within 10 years.Specify the type of model, a summary of the modelbuilding steps, and the method for internal validation NA External validation of Framingham-SP model; no model building.Specify the measures used to assess model performance (e.g., discrimination, calibration, clinical utility) Yes Abstract (Methods) C-statistic, mean calibration, absolute difference, and discordance.Results Report the number of participants and outcome events Yes Abstract (Results) 7,363 participants (3,692 women and 3,671 men); 664 events (211 among women and 453 among men).Summarise the predictors in the final model NA External validation of Framingham-SP model; no model building.Report model performance estimates (with confidence intervals)